Clinical trials: Movement Abnormalities
Parkinson Disease
Kinetic Tremor in Parkinsons Disease: Its Course Under Pramipexole (Mirapexin®) Treatment and Impact on Quality of Life
The study will compare the effect of pramipexole on different types of tremor and particularly kinetic tremor in early and advanced Parkinson's disease patients and will evaluate the course of tremor measured with spiralometry…
- Trial name
- NCT01100073
- Where
- 215 sites in Estonia, Latvia and 6 more
- Volunteers
- 1,703 people
- Sponsor
- Boehringer Ingelheim
Tremor, Essential
Efficacy, Safety, and Pharmacokinetics of ES-481 in Adult Patients With Essential Tremors
This Pilot Phase 2A study will investigate the safety, tolerability, and pharmacokinetics (PK) of ES-481 in adult patients with essential tremor.
- Trial name
- NCT05234762
- Testing
- ES-481
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- ES Therapeutics Australia Pty Ltd
Trientine Treatment for Wilson's Disease
A Retrospective Study to Assess the Clinical Efficacy and Safety of Trientine in Wilson's Disease Patients
This is a retrospective study to assess the clinical efficacy and safety of trientine in Wilson's disease patients
- Trial name
- NCT03299829
- Testing
- Trientine
- Where
- Taiwan
- Volunteers
- 48 people
- Sponsor
- Excelsior
Parkinson Disease
Pharmacokinetic of Levodopa Study in Healthy Males
The purpose of the study is to investigate PK of levodopa in plasma after repeated doses of 3 levodopa formulations given in combination with carbidopa and ODM-104 and compared to the PK of standard IR and CR levodopa…
- Trial name
- NCT03140956
- Testing
- Levodopa, carbidopa, ODM-104
- Where
- Finland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Parkinson Disease
A Prospective, Randomized, Controlled Trial to Test Safety and Effectiveness of Unilateral Exablate MR-guided Focused Ultrasound Subthalamotomy in Patients With Early-Stage Parkinson's Disease
This prospective, randomized, multicenter study aims to evaluate in Early-Stage Parkinson's Disease (ESPD) patients the safety and effectiveness of treatment with Exablate MRgFUS subthalamotomy vs best medical treatment.
- Trial name
- NCT06584383
- Testing
- Exablate MRgFUS subthalamotomy, Best Medical Treatment
- Where
- 4 sites in Chile, Germany and 1 more
- Volunteers
- 67 people
- Sponsor
- InSightec
Parkinson's Disease
Feasibility Study to Evaluate Deep Brain Stimulation (DBS) Settings for the Treatment of Parkinson's Disease
The purpose of this study is to assess the cognitive performance in patients with advanced Parkinson's disease receiving Deep Brain Stimulation (DBS) with settings predetermined clinically to settings derived from a…
- Trial name
- SAGE (NCT01230151)
- Testing
- GUIDE software, Version 0.1, Clinically defined stimulation parameters
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- Intelect Medical, Inc.
Tourette Syndrome
Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome
Phase 2, double-blind, placebo-controlled study to assess the safety and efficacy of NBI-98854 administered once daily (qd) for a total of 6 weeks of treatment.
- Trial name
- NCT02679079
- Testing
- NBI-98854
- Where
- 44 sites in United States
- Volunteers
- 98 people
- Sponsor
- Neurocrine Biosciences
Parkinson Disease
Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's Disease
This study evaluates the hypothesis that the gas mixture with xenon will have a positive effect on the symptoms in patients with Parkinson's Disease.
- Trial name
- NCT04097080
- Testing
- NBTX-001, Standard of Care
- Where
- 2 sites in Russia
- Volunteers
- 60 people
- Sponsor
- Nobilis Therapeutics Inc.
Parkinson's Disease
Efficacy of Nutritional Supplement VIUSID/ALZER in Patients With Parkinson's Disease
The purpose of the study is to evaluate whether Viusid/Alzer Nutritional supplements, could improve the progression disease, in patients with Parkinson's Disease (PD).
- Trial name
- NCT01016470
- Testing
- VIUSID/ALZER
- Where
- Cuba
- Volunteers
- 100 people
- Sponsor
- Catalysis SL
Parkinson Disease
Neurofeedback Rehabilitation With FES and VR for PD
recoveriX PRO system is a Brain-Computer Interface (BCI) device that combines Motor Imagination (MI), with Functional Electrical Stimulation (FES) and Virtual Reality (VR) as feedback devices.
- Trial name
- recoveriX PD (NCT06690931)
- Testing
- Brain-Computer Interface with FES and VR, Motor imagery with Functional Electrical Stimulation and Virtual Reality feedback
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- g.tec medical engineering GmbH
Parkinson's Disease (Disorder)
A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations
To evaluate the safety and efficacy of IPX203 (carbidopa and levodopa) extended-release capsules (IPX203 ER CD-LD) in comparison to immediate release (IR) CD-LD in the treatment of CD-LD-experienced participants with Parkinson's…
- Trial name
- NCT03670953
- Testing
- IR CD-LD, IPX203 ER CD-LD
- Where
- 108 sites in United States, Czechia and 6 more
- Volunteers
- 630 people
- Sponsor
- Impax Laboratories, LLC
Essential Tremor
GyroGlove Use in Essential Tremor Patients
This is a multi-centre, single-blind, placebo-controlled trial with an open label follow up. After the baseline assessment, all participants will receive the GyroGlove for two weeks during the open label follow up part of the…
- Trial name
- NCT05958030
- Testing
- GyroGlove
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 30 people
- Sponsor
- GyroGear Ltd
Angelman Syndrome, Fragile X Syndrome
Single Dose Pharmacokinetic (PK) Study
The trial is a Phase 1 Single Dose PK Study in Adolescent Subjects with Fragile X syndrome (FXS) or Angelman syndrome (AS). The primary objective of the study is to evaluate the pharmacokinetics (PK) of OV101 following a single 5…
- Trial name
- NCT03109756
- Testing
- OV101
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Ovid Therapeutics Inc.
Multiple System Atrophy, Parkinson Variant
A Trial of ONO-2808 in Participants With the Parkinsonian Subtype of Multiple System Atrophy (MSA-P)
The main goal of this clinical trial is to learn if ONO-2808 works to treat adults with the Parkinsonian subtype of Multiple System Atrophy (MSA-P).
- Trial name
- NCT07825402
- Testing
- ONO-2808
- Volunteers
- 486 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Multiple System Atrophy (MSA), Healthy Adult
Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies
This is a single-center, open-label clinical study designed to evaluate the imaging characteristics and safety of [¹⁸F]MODAG-009 in participants with Parkinson's disease (PD), Multiple system atrophy (MSA), and Healthy controls…
- Conditions
- Multiple System Atrophy (MSA), Healthy Adult, Parkinson Disease
- Trial name
- MODAG-009-P1-0 (NCT07640555)
- Testing
- [¹⁸F]MODAG-009 PET imaging
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- MODAG GmbH
Huntington's Disease
Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of OMS643762 (the study drug) in subjects with Huntington's disease (HD).
- Trial name
- NCT02074410
- Testing
- OMS643762
- Where
- 9 sites in United States
- Volunteers
- 22 people
- Sponsor
- Omeros Corporation
Wilson Disease
Phase I/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of GC310 Injection in Patients With Wilson's Disease (WD)
The goal of this clinical trial is to learn if GC310 (AAV5-ATP7B) gene therapy can treat Wilson's Disease (WD) in patients over the age of 18 years old.
- Trial name
- NCT07173933
- Testing
- GC310
- Where
- China
- Volunteers
- 15 people
- Sponsor
- GeneCradle Inc
Parkinson Disease
Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics
To investigate the effect of four single oral doses of BIA 6-512 (25 mg, 50 mg, 100 mg and 200 mg) on levodopa pharmacokinetics when administered in combination with a single-dose of controlled release levodopa/benserazide 100/25…
- Trial name
- NCT03091543
- Testing
- Madopar® HBS 125, BIA 6-512 25 mg dose, BIA 6-512 50 mg dose
- Where
- Portugal
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease
To assess the efficacy of rasagiline 1 mg as a first add-on treatment to dopamine agonist therapy in early Parkinson Disease (PD) patients, , not optimally controlled on dopamine agonists as compared to placebo.
- Trial name
- ANDANTE (NCT01049984)
- Testing
- Rasagiline
- Where
- 58 sites in United States
- Volunteers
- 328 people
- Sponsor
- Teva Neuroscience, Inc.
Parkinson's Disease
Study of KW-6002 (Istradefylline) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
The purpose of this study is to establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the mean total hours of awake time per day spent in the OFF state in patients with advanced Parkinson's…
- Trial name
- 6002-009 (NCT00955526)
- Testing
- Istradefylline
- Where
- Japan
- Volunteers
- 373 people
- Sponsor
- Kyowa Kirin Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.